Free Access
Reprod. Nutr. Dev.
Volume 45, Number 1, January-February 2005
Page(s) 1 - 28
References of Reprod. Nutr. Dev. 45 1-28
  1. Voss A, Reinhart M, Sankarappa S, Sprecher H. The metabolism of 7,10,13,16,19-docosapentaenoic acid to 4,7,10,13,16,19-docosahexaenoic acid in rat liver is independent of a 4-desaturase. J Biol Chem 1991, 266: 19995-20000.
  2. Emken EA, Adolf RO, Gulley RM. Dietary linoleic acid influences desaturation and acylation of deuterium-labeled linoleic and linolenic acids in young adult males. Biochim Biophys Acta 1994, 1213: 277-288.
  3. Salem N Jr, Wegher B, Mena P, Uauy R. Arachidonic acid and docosahexaenoic acid are biosynthesized from their 18-carbon precursors in human infants. Proc Natl Acad Sci USA 1996, 93: 49-54.
  4. Burdge G. Alpha-linolenic acid metabolism in men and women: nutritional and biological implications. Curr Opin Clin Nutr 2004, 7: 137-144.
  5. Conquer JA, Holub BJ. Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. J Nutr 1996, 126: 3032-3039.
  6. Conquer JA, Holub BJ. Dietary docosahexaenoic acid as a source of eicosapentaenoic acid in vegetarians and omnivores. Lipids 1997, 32: 341-345.
  7. Simopolous AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr 1999, 70: S560-S569.
  8. Simopolous AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991, 54: 438-463.
  9. Kris-Etherton PM, Shaffer D, Yu-Poth S, Huth P, Moriarty K, Fishell V, Hargrove RL, Zhao G, Etherton TD. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr 2000, 71: S179-S188.
  10. Howe PR, Meyer BJ, Record S, Baghurst K. Contribution of red meat to very long chain omega-3 fatty acid (VLCOmega3) intake. Asia Pac J Clin Nutr 2003, 12 (Suppl): S27.
  11. Institute of Medicine (IOM). Dietary References Intakes for Energy and Macronutrients. National Academy Press, Washington, 2002.
  12. British Nutrition Foundation. Task Force on Unsaturated Fatty Acids. Chapman and Hall, London, 1992.
  13. Sugano M, Hirahara F. Polyunsaturated fatty acids in the food chain in Japan. Am J Clin Nutr 2000, 71: 189S-196S.
  14. Sastry PS. Lipids of nervous tissue: composition and metabolism. Prog Lipid Res 1985, 24: 69-176.
  15. Dennis EA. Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 1994, 269: 13057-13060.
  16. Balboa MA, Varela-Nieto I, Killermann Lucas K, Dennis EA. Expression and function of phospholipase A(2) in brain. FEBS Lett 2002, 531: 12-17.
  17. Molloy GY, Rattray M, Williams RJ. Genes encoding multiple forms of phospholipase A2 are expressed in rat brain. Neurosci Lett 1998, 258: 139-142.
  18. Jarrard LE. On the role of the hippocampus in learning and memory in the rat. Behav Neural Biol 1993, 60: 9-26.
  19. Farooqui AA, Yang HC, Rosenberger TA, Horrocks LA. Phospholipase A2 and its role in brain tissue. J Neurochem 1997, 69: 889-901.
  20. Farooqui AA, Horrocks LA. Brain phospholipase A2: a perspective on the history. Prostaglandins Leukot Essent Fatty Acids 2004, 71: 161-169.
  21. Gattaz WF, Hubner CV, Nevalainen TJ, Thuren T, Kinnunen PK. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol Psychiatry 1990, 28: 495-501.
  22. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG, Allen M. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 1991, 48: 563-568.
  23. Horrobin DF, Glen AI, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res 1994, 13: 195-207.
  24. Wei J, Hemmings GP. A study of a genetic association between the PTGS2/PA2G4A locus and schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2004, 70: 413-415.
  25. MacDonell LE, Skinner FK, Ward PE, Glen AI, Glen AC, Macdonald DJ, Boyle RM, Horrobin DF. Increased levels of cytosolic phospholipase A2 in dyslexics. Prostaglandins Leukot Essent Fatty Acids 2000, 63: 37-39.
  26. Noponen M, Sanfilipo M, Samanich K, Ryer H, Ko G, Angrist B, Wolkin A, Duncan E, Rotrosen J. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol Psychiatry 1993, 34: 641-649.
  27. Chang MC, Jones CR. Chronic lithium treatment decreases brain phospholipase A(2) activity. Neurochem Res 1998, 23: 887-892.
  28. Horrobin DF, Bennett CN. Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Prostaglandins Leukot Essent Fatty Acids 1999, 60: 217-234 [CrossRef].
  29. Ghelardoni S, Tomita YA, Bell JM, Rapoport SI, Bosetti F. Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Psychiatry 2004, 56: 248-254.
  30. Papadimitriou GN, Dikeos DG, Souery D, Del-Favero J, Massat I, Avramopoulos D, Blairy S, Cichon S, Ivezic S, Kaneva R, Karadima G, Lilli R, Milanova V, Nothen M, Oruc L, Rietschel M, Serretti A, Van Broeckhoven C, Stefanis CN, Mendlewicz J. Genetic association between the phospholipase A2 gene and unipolar affective disorder: a multicentre case-control study. Psychiatr Genet 2003, 13: 211-220.
  31. Meira-Lima I, Jardim D, Junqueira R, Ikenaga E, Vallada H. Allelic association study between phospholipase A2 genes and bipolar affective disorder. Bipolar Disord 2003, 5: 295-299.
  32. Ross BM, Turenne S, Moszczynska A, Warsh JJ, Kish SJ. Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. Brain Res 1999, 821: 407-413.
  33. Finnen MJ, Lovell CR. Purification and characterization of phospholipase A2 from human epidermis. Biochem Soc Trans 1991, 19: 91S.
  34. Emsley R, Myburgh C, Oosthiuzen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002, 159: 1596-1598 [CrossRef].
  35. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega-3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999, 56: 407-412.
  36. Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatr Scand 1988, 78: 587-592.
  37. Mellor JE, Laugharne JD, Peet M. Omega-3 fatty acid supplementation in schizophrenia patients. Hum Psychopharmacol 1996, 11: 39-46.
  38. Maes M, Stevens WJ, Declerck LS, Bridts CH, Peeters D, Schotte C, Cosyns P. Significantly increased expression of T-cell activation markers (interleukin-2 and HLA-DR) in depression: further evidence for an inflammatory process during that illness. Prog Neuropsychopharmacol Biol Psychiatry 1993, 17: 241-255.
  39. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995, 29: 141-152.
  40. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, Scharpe S. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 1997, 66: 1-11 [CrossRef].
  41. Segman RH, Meltzer A, Gross-Tsur V, Kosov A, Frisch A, Inbar E, Darvasi A, Levy S, Goltser T, Weizman A, Galili-Weisstub E. Preferential transmission of interleukin-1 receptor antagonist alleles in attention deficit hyperactivity disorder. Mol Psychiatry 2002, 7: 72-74.
  42. Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 2001, 120: 170-179.
  43. Croonenberghs J, Bosmans E, Deboutte D, Kenis G, Maes M. Activation of the inflammatory response system in autism. Neuropsychobiology 2002, 45: 1-6.
  44. Bousserouel S, Brouillet A, Bereziat G, Raymondjean M, Andreani M. Different effects of n-6 and n-3 polyunsaturated fatty acids on the activation of rat smooth muscle cells by interleukin-1 beta. J Lipid Res 2003, 44: 601-611.
  45. Hardardottir I, Kinsella JE. Tumor necrosis factor production by murine resident peritoneal macrophages is enhanced by dietary n-3 polyunsaturated fatty acids. Biochim Biophys Acta 1991, 1095: 187-195.
  46. Song C, Leonard BE, Horrobin DF. Dietary ethyl-eicosapentaenoic acid but not soybean oil reverses central interleukin-1-induced changes in behavior, corticosterone and immune response in rats. Stress 2004, 7: 43-54.
  47. Song C, Horrobin D. Omega-3 fatty acid ethyl-eicosapentaenoate, but not soybean oil, attenuates memory impairment induced by central IL-1 beta administration. Lipid Res 2004, 45: 1112-1121.
  48. Kinsella JE, Broughton KS, Whelan JW. Dietary unsaturated fatty acids: interactions and possible needs in relation to eicosanoid synthesis. J Nutr Biochem 1990, 1: 123-141.
  49. Youdim KA, Martin A, Joseph JA. Essential fatty acids and the brain: possible health implications. Int J Dev Neuroscience 2000, 28: 383-399.
  50. Guyton AC, Hall JE. Textbook of Medical Physiology. 9th ed. WB Saunders CO, PN, 1996, 569 p.
  51. Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci 2004, 5: 483-494 [CrossRef].
  52. Baldwin D, Rudge S. The role of serotonin in depression and anxiety. Int Clin Psychopharmacol 1995, 9: S41-S45.
  53. Fernstrom JD. Dietary amino acids and brain function. Am Diet Assoc 1994, 94: 71-77.
  54. Paez X, Hernandez L. Simultaneous brain and blood microdialysis study with a new removable venous probe. Serotonin and 5-hydroxy indolacetic acid changes after D-norfenfluramine or fluoxetine. Life Sci 1996, 58: 1209-1221.
  55. Post RM, Jimerson DC, Bunney WE Jr, Goodwin FK. Dopamine and mania: behavioral and biochemical effects of the dopamine receptor blocker pimozide. Psychopharmacology (Berl) 1980, 67: 297-305.
  56. Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998, 44: 1090-1098.
  57. Ogilvie AD, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwim GM, Smith CA. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 1996, 347: 731-733.
  58. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry 2001, 58: 539-544.
  59. Elliot H. Attention deficit hyperactivity disorder in adults: a guide for the primary care physician. South Med J 2002, 95: 736-742.
  60. Cook EH, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995, 56: 993-998.
  61. Qian Q, Wang Y, Zhou R, Yang L, Faraone SV. Family-based and case-control association studies of DRD4 and DAT1 polymorphisms in Chinese attention deficit hyperactivity disorder patients suggest long repeats contribute to genetic risk for the disorder. Am J Med Genet 2004, 128B: 84-89.
  62. Levitan RD, Masellis M, Basile VS, Lam RW, Jain U, Kaplan AS, Kennedy SH, Siegel G, Walker ML, Vaccarino FJ, Kennedy JL. Polymorphism of the serotonin-2A receptor gene (HTR2A) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder. J Affect Disord 2002, 71: 229-233.
  63. Richardson AJ, Ross MA. Fatty acid metabolism in neurodevelopmental disorder: a new perspective on associations between attention-deficit/hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukot Essent Fatty Acids 2000, 63: 1-9 [CrossRef].
  64. Marino C, Giorda R, Vanzin L, Molteni M, Lorusso ML, Nobile M, Baschirotto C, Alda M, Battaglia M. No evidence for association and linkage disequilibrium between dyslexia and markers of four dopamine-related genes. Eur Child Adolesc Psychiatry 2003, 12: 198-202.
  65. Nopola-Hemmi J, Myllyluoma B, Haltia T, Taipale M, Ollikainen V, Ahonen T, Voutilainen A, Kere J, Widen E. A dominant gene for developmental dyslexia on chromosome 3. J Med Genet 2001, 38: 658-664.
  66. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 2004, 7: S1-S5.
  67. Carlsson A, Lindqvist M. Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963, 20: 140-144.
  68. Lieberman JA, Kane JM, Gadaleta D, Brenner R, Lesser MS, Kinon B. Methylphenidate challenge as a predictor of relapse in schizophrenia. Am J Psychiatry 1984, 141: 633-638.
  69. Glatt SJ, Faraone SV, Tsuang MT. Meta-analysis identifies an association between the dopamine D2 receptor gene and schizophrenia. Mol Psychiatry 2003, 8: 911-915.
  70. Ambrosio AM, Kennedy JL, Macciardi F, Macedo A, Valente J, Dourado A, Oliveira CR, Pato C. Family association study between DRD2 and DRD3 gene polymorphisms and schizophrenia in a Portuguese population. Psychiatry Res 2004, 125: 185-191.
  71. Glatt SJ, Faraone SV, Tsuang MT. DRD2 -141C insertion/deletion polymorphism is not associated with schizophrenia: results of a meta-analysis. Am J Med Genet B 2004, 128: 21-23.
  72. Wooley D, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA 1954, 40: 228-231.
  73. Fink H, Morgenstern R, Oelssner W. Clozapine-A serotonin antagonist? Pharmacol Biochem Behav 1984, 20: 513-517.
  74. DeLeon A, Patel NC, Lynn Crismon M. Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004, 26: 649-666 [CrossRef].
  75. Castensson A, Emilsson L, Sundberg R, Jazin E. Decrease of serotonin receptor 2C in schizophrenia brains identified by high-resolution mRNA expression analysis. Biol Psychiatry 2003, 54: 1212-1221.
  76. Dubertret C, Hanoun N, Ades J, Hamon M, Gorwood P. Family-based association study of the serotonin-6 receptor gene (C267T polymorphism) in schizophrenia. Am J Med Genet B 2004, 126: 10-15.
  77. Ellingrod VL, Miller D, Ringold JC, Perry PJ. Distribution of the serotonin 2C (5HT2C) receptor gene -759C/T polymorphism in patients with schizophrenia and normal controls. Psychiatr Genet 2004, 14: 93-95.
  78. De la Presa Owens S, Innis SM. Docosahexaenoic acid and arachidonic acid prevent a decrease in dopaminergic and serotoninergic neurotransmitters in frontal cortex caused by a linoleic and alpha-linolenic acid deficient diet in formula-fed piglets. J Nutr 1999, 129: 2088-2093.
  79. Austead N, Innis SM, de la Presa Owens S. Auditory evoked response and brain phospholipid fatty acids and monoamines in rats fed formula with and without arachidonic acid (AA) and/or docosahexaenoic acid (DHA). In: Watkins P, Spector A, Hamilton J, Katz R (Eds), Brain uptake and utilization of fatty acids: applications to peroxisomal biogenesis disorders, Maryland: National Institutes of Health Conference, 2000, p 3.
  80. Zimmer L, Durand G, Guilloteau D, Chalon S. n-3 polyunsaturated fatty acid deficiency and dopamine metabolism in the rat frontal cortex. Lipids 1999, 34: S251.
  81. Zimmer L, Delpal S, Guilloteau D, Aioun J, Durand G, Chalon S. Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neurosci Lett 2000, 284: 25-28.
  82. Chalon S, Delion-Vancassel S, Belzung C, Guilloteau D, Leguisquet A, Besnard JC, Durand G. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr 1998, 128: 2512-2519.
  83. Kodas E, Galineau L, Bodard S, Vancassel S, Guilloteau D, Besnard JC, Chalon S. Serotinergic neurotransmission is affected by n-3 polyunsaturated fatty acids in the rat. Neurochem 2004, 89: 695-702.
  84. Sirvio J. Strategies that support declining cholinergic neurotransmission in Alzheimer's disease patients. Gerontology 1999, 45 (Suppl 1): 3-14.
  85. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS, Egan MF, Coppola R, Weinberger DR. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003, 160: 118-127.
  86. Leiva DB. The neurochemistry of mania: a hypothesis of etiology and rationale for treatment. Prog Neuropsychopharmacol Biol Psychiatry 1990, 14: 423-429.
  87. Favreliere S, Perault MC, Huguet F, De Javel D, Bertrand N, Piriou A, Durand G. DHA-enriched phospholipid diets modulate age-related alterations in rat hippocampus. Neurobiol Aging 2003, 24: 233-243.
  88. Minami M, Kimura S, Endo T, Hamaue N, Hirafuji M, Togashi H, Matsumoto M, Yoshioka M, Saito H, Watanabe S, Kobayashi T, Okuyama H. Dietary docosahexaenoic acid increases cerebral acetylcholine levels and improves passive avoidance performance in stroke-prone spontaneously hypertensive rats. Pharmacol Biochem Behav 1997, 58: 1123-1129.
  89. Aid S, Vancassel S, Poumes-Ballihaut C, Chalon S, Guesnet P, Lavialle M. Effect of a diet-induced n-3 PUFA depletion on cholinergic parameters in the rat hippocampus. Lipid Res 2003, 44: 1545-1551.
  90. Piomelli D. Eicosanoids in synaptic transmission. Crit Rev Neurobiology 1994, 8: 65-82.
  91. Di Marzo V, Piomelli D. Participation of prostaglandin E2 in dopamine D2 receptor-dependent potentiation of arachidonic acid release. J Neurochem 1992, 59: 379-382.
  92. Ahmadi S, Lippross S, Neuhuber WL, Zeilhofer HU. PGE(2) selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci 2002, 5: 34-40.
  93. Wolfe L, Horrocks L. Eicosanoids. In: Seigel GJ, Agranoff BW, Albers RW, Molinoff PB (Eds), Basic Neurochemistry: Molecular, Cellular, and Medical Aspects, 5th ed, Raven Press, New York, 1994, p 475-490.
  94. Schlicker E, Fink K, Gothert M. Influence of eicosanoids on serotonin release in the rat brain: inhibition by prostaglandins E1 and E2. Naunyn Schmiedebergs Arch Pharmacol 1987, 335: 646-651.
  95. Rettori V, Gimeno M, Lyson K, McCann SM. Nitric oxide mediates norepinephrine-induced prostaglandin E2 release from the hypothalamus. Proc Natl Acad Sci USA 1992, 89: 11543-11546.
  96. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996, 19: 1-17.
  97. Groff JL, Gropper SS, Hunt SM. Advanced Nutrition and Human Metabolism. 2nd ed. West Publishing Co, MN, 1995.
  98. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and $\omega$-3 essential fatty acid supplementation in schizophrenia. Prog Neuro Psychoparmacol Biol Psychiatr 2001, 25: 463-493.
  99. Rosler M, Retz W, Thome J, Riederer P. Free radicals in Alzheimer's dementia: currently available therapeutic strategies. J Neural Transm Suppl 1998, 54: 211-219.
  100. Ross MA. Could oxidative stress be a factor in neurodevelopmental disorders? Prostaglandins Leukot Essent Fatty Acids 2000, 63: 61-63.
  101. Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004, 49: 205-209.
  102. Lukash AI, Zaika VG, Kucherenko AO, Miliutina NP. Free radical processes and antioxidant system in depression and treatment efficiency. Zh Nevrol Psikhiatr Im S S Korsakova 2002, 102: 41-44.
  103. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003, 8: 365-370.
  104. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004, 19: 89-95.
  105. Tsuboi H, Shimoi K, Kinae N, Oguni I, Hori R, Kobayashi F. Depressive symptoms are independently correlated with lipid peroxidation in a female population: comparison with vitamins and carotenoids. J Psychosom Res 2004, 56: 53-58.
  106. Ross BM, McKenzie I, Glen I, Bennett CP. Increased levels of ethane, a non-invasive marker of n-3 fatty acid oxidation, in breath of children with attention deficit hyperactivity disorder. Nutr Neurosci 2003, 6: 277-281 [CrossRef].
  107. Yao JK, Reddy R, van Kammen DP. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000, 97: 137-151.
  108. Stokiasova A, Zapletalek M, Kudrnova K, Randova Z. Glutathione peroxidase activity of blood in chronic schizophrenics. Sb Ved Pr Lek Fak Karlovi University Hradci Kralove 1986, 20: 103-108.
  109. Reddy R, Mahadik SP, Mukherjee S, Murthy JN. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry 1991, 20: 409-412.
  110. Cecchi C, Fiorillo C, Sorbi S, Latorraca S, Nacmias B, Bagnoli S, Nassi P, Liguri G. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic Biol Med 2002, 33: 1372-1379.
  111. Perry G, Castellani RJ, Smith MA, Harris PL, Kubat Z, Ghanbari K, Jones PK, Cordone G, Tabaton M, Wolozin B, Ghanbari H. Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol (Berl) 2003, 106: 552-556.
  112. Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts LJ 2nd, Morrow JD, Montine TJ. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 2004, 28: 117-124.
  113. Hargreaves KM, Clandinin MT. Dietary control of diacylphosphatidylethanolamine species in brain. Biochim Biophys Acta 1998, 962: 98-104.
  114. Bjerve KS, Brubakk AM, Fougner KJ, Johnsen H, Midthjell K, Vik T. Omega-3 fatty acids: essential fatty acids with important biological effects, and serum phospholipid fatty acids as markers of dietary omega 3-fatty acid intake. Am J Clin Nutr 1993, 57: 801S-805S.
  115. Godley PA, Campbell MK, Miller C, Gallagher P, Martinson FE, Mohler JL, Sandler RS. Correlation between biomarkers of omega-3 fatty acid consumption and questionnaire data in African American and Caucasian United States males with and without prostatic carcinoma. Cancer Epidemiol Biomarkers Prev 1996, 5: 115-119.
  116. Hjartaker J, Lund E, Bjerve KS. Serum phospholipid fatty acid composition and habitual intake of marine foods registered by a semi-quantitative food frequency questionnaire. Eur J Clin Nutr 1997, 51: 736-742.
  117. Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 2003, 35: 772-781.
  118. Mori TA, Puddey IB, Burke V, Croft KD, Dunstan DW, Rivera JH, Beilin LJ. Effect of omega-3 fatty acids on oxidative stress in humans: GC-MS measurement of urinary F2-isoprostane excretion. Redox Rep 2000, 5: 45-46.
  119. Songur A, Sarsilmaz M, Sogut S, Ozyurt B, Zararsiz I, Turkoglu AO. Hypothalamic superoxide dismutase, xanthine oxidase, nitric oxide, and malondialdehyde in rats fed with fish omega-3 fatty acids. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28: 693-698 [CrossRef].
  120. Barbosa DS, Cecchini R, El Kadri MZ, Rodriguez MA, Burini RC, Dichi I. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. Nutrition 2003, 19: 837-842.
  121. Barden AE, Mori TA, Dunstan JA, Taylor AL, Thornton CA, Croft KD, Beilin LJ, Prescott SL. Fish oil supplementation in pregnancy lowers F2-isoprostanes in neonates at high risk of atopy. Free Radic Res 2004, 38: 233-239.
  122. Xiao YF, Kang JX, Morgan JP, Leaf A. Blocking effects of polyunsaturated fatty acids on Na+ channels of neonatal rat ventricular myocytes. Proc Natl Acad Sci USA 1995, 92: 11000-11004.
  123. Kang JX, Leaf A. Evidence that free polyunsaturated fatty acids modify Na+ channels by directly binding to the channel proteins. Proc Natl Acad Sci USA 1996, 93: 3542-3546 [CrossRef].
  124. Vreugdenhil M, Bruehl C, Voskuyl RA, Kang JX, Leaf A, Wadman WJ. Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. Proc Natl Acad Sci USA 1996, 93: 12559-12563.
  125. Renganathan M, Godoy CM, Cukierman S. Direct modulation of Na+ currents by protein kinase C activators in mouse neuroblastoma cells. J Membr Biol 1995, 144: 59-69.
  126. Bogdanov KY, Spurgeon HA, Vinogradova TM, Lakatta EG. Modulation of the transient outward current in adult rat ventricular myocytes by polyunsaturated fatty acids. Am J Physiol 1998, 274: H571-H579.
  127. Seebungkert B, Lynch JW. Effects of polyunsaturated fatty acids on voltage-gated K+ and Na+ channels in rat olfactory receptor neurons. Eur J Neurosci 2002, 16: 2085-2094 [CrossRef].
  128. Honore E, Barhanin J, Attali B, Lesage F, Lazdunski M. External blockade of the major cardiac delayed-rectifier K+ channel (Kv1.5) by polyunsaturated fatty acids. Proc Natl Acad Sci USA 1994, 91: 1937-1944.
  129. Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M. Polyunsaturated fatty acids are potent neuroprotectors. EMBO 2000, 19: 1784-1793.
  130. Heurteaux C, Guy N, Laigle C, Blondeau N, Duprat F, Mazzuca M, Lang-Lazdunski L, Widmann C, Zanzouri M, Romey G, Lazdunski M. TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO 2004, 23: 2684-2695.
  131. Xiao YF, Gomez AM, Morgan JP, Lederer WJ, Leaf A. Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci USA 1997, 94: 4182-4187 [CrossRef].
  132. Turner N, Else PL, Hulbert AJ. Docosahexaenoic acid (DHA) content of membranes determines molecular activity of the sodium pump: implications for disease states and metabolism. Naturwissenschaften 2003, 90: 521-523.
  133. Kearns SD, Haag M. The effect of omega-3 fatty acids on Ca-ATPase in rat cerebral cortex. Prostaglandins Leukot Essent Fatty Acids 2002, 67: 303-308.
  134. Gegelashvili G, Schousboe A. High affinity glutamate transporters: regulation of expression and activity. Mol Pharmacol 1997, 52: 6-15.
  135. Nishikawa M, Kimura S, Akaike N. Facilitatory effect of docosahexaenoic acid on N-methyl-D-aspartate response in pyramidal neurons of rat cerebral cortex. J Physiol 1994, 475: 83-93.
  136. Graber R, Sumida C, Nunez EA. Fatty acids and cell signal transduction. J Lipid Mediat Cell Signal 1994, 9: 91-116.
  137. Kogteva GS, Bezuglov VV. Unsaturated fatty acids as endogenous bioregulators. Biochemistry (Moscow) 1998, 63: 6-15.
  138. Wahle KW, Rotondo D, Heys SD. Polyunsaturated fatty acids and gene expression in mammalian systems. Proc Nutr Soc 2003, 62: 349-360.
  139. Horrocks LA, Farooqui AA. Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot Essent Fatty Acids 2004, 70: 361-372.
  140. Kitajka K, Puskas LG, Zvara A, Hackler L Jr, Barcelo-Coblijn G, Yeo YK, Farkas T. The role of n-3 polyunsaturated fatty acids in brain: modulation of rat brain gene expression by dietary n-3 fatty acids. Proc Natl Acad Sci USA 2002, 99: 2619-2624.
  141. George JM, Jin H, Woods WS, Clayton DF. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995, 15: 361-372.
  142. Huntley GW, Gil O, Bozdagi O. The cadherin family of cell adhesion molecules: multiple roles in synaptic plasticity. Neuroscientist 2002, 8: 221-233.
  143. Junge HJ, Rhee JS, Jahn O, Varoqueaux F, Spiess J, Waxham MN, Rosenmund C, Brose N. Calmodulin and Munc13 form a Ca2+ sensor/effector complex that controls short-term synaptic plasticity. Cell 2004, 118: 389-401 [CrossRef].
  144. Colbran RJ, Brown AM. Calcium/calmodulin-dependent protein kinase II and synaptic plasticity. Curr Opin Neurobiol 2004, 14: 318-327.
  145. Li H, Sanchez-Torres J, Del Carpio A, Salas V, Villalobo A. The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein. Biochem J 2004, 381: 257-266.
  146. Schmitt JM, Wayman GA, Nozaki N, Soderling TR. Calcium activation of ERK mediated by calmodulin kinase I. J Biol Chem 2004, 279: 24064-24072.
  147. Kitajka K, Sinclair AJ, Weisinger RS, Weisinger HS, Mathai M, Jayasooriya AP, Halver JE, Puskas LG. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc Natl Acad Sci USA 2004, 101: 10931-10936.
  148. Martinez M. Polyunsaturated fatty acids in the developing human brain, erythrocytes and plasma in peroxisomal disease: therapeutic implications. J Inherit Metab Dis 1995, 18 (Suppl 1): 61-75.
  149. Uauy R, Peirano P, Hoffman D, Mena P, Birch D, Birch E. Role of essential fatty acids in the function of the developing nervous system. Lipids 1996, 31 (Suppl): S167-S176.
  150. Hoffman DR, Birch DG. Omega-3 fatty acid status in patients with retinitis pigmentosa 1998, 83: 52-60.
  151. Martinez M. Restoring the DHA levels in the brains of Zellweger patients. J Mol Neurosci 2001, 16: 309-316.
  152. Pary R, Lewis S, Matuschka PR, Lippmann S. Attention-deficit/hyperactivity disorder: an update. South Med 2002, 95: 743-749.
  153. Richardson AJ, Puri BK. The potential role of fatty acids in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2000, 63: 79-87.
  154. Burgess JR, Stevens L, Zhang W, Peck L. Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am J Clin Nutr 2000, 71: 327-330.
  155. Spencer T, Biederman J, Wilens TE, Faraone SV. Is attention deficit hyperactivity disorder in adults a valid disorder? Harv Rev Psychiatry 1994, 1: 326-335.
  156. Mitchell EA, Aman MG, Turbott SH, Manku M. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin Pediatr 1987, 26: 406-411.
  157. Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA, Lipp SR, Burgess JR. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 1995, 62: 761-768.
  158. Young GS, Maharaj NJ, Conquer JA. Blood phospholipid fatty acid analysis of adults with and without attention deficit/hyperactivity disorder. Lipids 2004, 39: 117-123.
  159. Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 2001, 139: 189-196 [CrossRef].
  160. Richardson AJ, Puri BK. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuro-Psychopharmacol Biol Psychiatry 2002, 26: 233-239.
  161. Stevens L, Zhang W, Peck L, Kuczek T, Grevsted N, Mahon A, Zentall SS, Arnold E, Burgess JR. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviours. Lipids 2003, 38: 1007-1021.
  162. Harding KL, Judah RD, Gant CE. Outcome-based comparison of ritalin versus food-supplement treated children with AD/HD. Altern Med Rev 2003, 8: 319-330.
  163. Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder-a placebo-controlled double-blind study. Eur J Clin Nutr 2004, 58: 467-473.
  164. Evans DA, Funkenstein HH, Alber M, Scherr PA, Cook NR, Chown M, Herbert L, Hennekens C, Taylor J. Prevalence of Alzheimer's disease in a community population of older persons: higher that previously reported. J Am Med Assoc 1989, 262: 2551-2556.
  165. Nitsch R, Pittas A, Blustztajn JK, Slock BE, Growdon J. Alterations of phospholipid metabolites in post-mortem brains from patients with Alzheimer's disease. Ann NY Acad Sci 1991, 640: 110-113.
  166. Soderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and Alzheimer's disease. Lipids 1991, 26: 421-428.
  167. Soderberg M, Edlund C, Kristensson K, Alafuzoff I, Dallner G. Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type. J Neurochem 1992, 59: 1646-1653.
  168. Coorigan FM, Horrobin DF, Skinner ER, Besson JA, Cooper MB. Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampus cortex from Alzeimer's disease patients and its relationship to acetyl CoA content. Int J Biochem Cell Biol 1998, 30: 197-207.
  169. Mulder M, Ravid R, Swaab DF, deLoet ER, Haasdijk ED, Julk J, van der Bloom J, Havekes LM. Reduced levels of cholesterol, phospholipids, and fatty acids in CSF of Alzheimer's disease patients are not related to Apo E4. Alzheimer Dis Assoc Disord 1998, 12: 198-203.
  170. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 1998, 23: 81-88.
  171. Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF. Fish, meat, and risk of dementia: cohort study. Br Med J 2002, 325: 932-933.
  172. Larrieu S, Letenneur L, Helmer, C, Dartigues JF, Barberger-Gateau P. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J. Nutr Health Aging 2004, 8: 150-154.
  173. Grant WB. Dietary Links to Alzheimer's Disease. Alzheimer Dis Rev 1997, 2: 42-55.
  174. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 1997, 145: 33-41.
  175. Grant WB. Diet and risk of dementia: Does fat matter? The Rotterdam study. Neurology 2003, 60: 2020-2021.
  176. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, Schneider J. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003, 60: 940-946.
  177. Kalmijn S, van Boxtel MPJ, Ocke M, Verschuren WMM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology 2004, 62: 275-280.
  178. Heude B, Ducimetiere P, Berr C. Cognitive decline and fatty acid composition of erythrocyte membranes. The EVA study 2003, 77: 803-808.
  179. Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, Coakley D, Gibney MJ. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 2003, 89: 483-489.
  180. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimer's Disease, other types of dementia and cognitive impairment. Lipids 2000, 35: 1305-1312.
  181. Laurin D, Verreault R, Lindsay J, Dewailly E, Holub BJ. Omega-3 fatty acids and risk of cognitive impairment and dementia. J Alzheimer Dis 2003, 5: 315-322.
  182. Otsuka M, Yamaguchi K, Ueki A. Similarities and differences between Alzheimer's disease and vascular dementia from the viewpoint of nutrition. Ann NY Acad Sci 2002, 977: 155-161.
  183. Otsuka M. Analysis of dietary factors in Alzheimer's disease: clinical use of nutritional intervention for prevention and treatment of dementia. Nippon Ronen Igakkai Zasshi 2000, 37: 970-973.
  184. Kyle DJ, Schaefer E, Patton G, Beiser A. Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids 1999, 34 (Suppl): S245.
  185. Nourooz-Zadeh J, Liu EH, Yhlen B, Anggard EE, Halliwell B. F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J Neurochem 1999, 72: 734-740.
  186. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD. Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999, 52: 562-565.
  187. Terano T, Fujishiro S, Ban T, Yamamoto K, Tanaka T, Noguchi Y, Tamura Y, Yazawa K, Hirayama T. Docosahexaenoic acid supplementation improves the moderately severe dementai from thrombotic cerebrovascular diseases. Lipids 1999, 34: S345-S346.
  188. Suzuki H, Morikawa Y, Takahashi H. Effect of DHA oil supplementation on intelligence and visual acuity in the elderly. World Rev Nutr 2001, 88: 68-71.
  189. Christensen O, Christenesen E. Fat consumption and schizophrenia. Acta Psychiatr Scand 1988, 78: 587-591.
  190. Mellor JE, Laugharne JDE, Peet M. Omega-3 fatty acid supplementation in schizophrenia patients. Hum Psychopharmacol 1996, 11: 39-46.
  191. Richardson AJ, Cyhlarova E, Ross MA. Omega-3 and omega-6 fatty acid concentrations in red blood cell membranes relate to schizotypal traits in healthy adults. Prostaglandins Leukot Essent Fatty Acids 2003, 69: 461-466.
  192. Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids 2003, 69: 393-399.
  193. Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, Bennett C, Ranjekar PK, Mahadik SP. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 2003, 53: 56-64.
  194. Khan MM, Evands DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002, 58: 1-10.
  195. Assies J, Lieverse R, Vreken P, Wanders RJ, Dingemans PM, Linszen DH. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol Psychiatry 2001, 49: 510-522.
  196. Peet M, Laugharne J, Rangarajan N, Horrobin D, Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 1995, 29: 227-232.
  197. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB, Mahadik SP. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121: 109-122.
  198. Laugharne JD, Mellor JE, Peet M. Fatty acids and schizophrenia. Lipids 1996, 31 (Suppl): S163-S165.
  199. Mahadik SP, Mukherjee S, Horrobin DF, Jenkins K, Correnti EE, Scheffer RE. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res 1996, 63: 133-142.
  200. Fischer S, Kissling W, Kuss HJ. Schizophrenic patients treated with high dose phenothiazine or thioxanthene become deficient in polyunsaturated fatty acids in their thrombocytes. Biochem Pharmacol 1992, 44: 317-323.
  201. Hibbeln JR, Makino KK, Martin CE, Dickerson F, Boronow J, Fenton WS. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biol Psychiatry 2003, 53: 431-441 [CrossRef].
  202. Mahadik SP, Shendarkar NS, Scheffer RE, Mukherjee S, Correnti EE. Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls. Prostaglandins Leukot Essent Fatty Acids 1996, 55: 65-70.
  203. Warner R, Laugharne J, Peet M, Brown L, Rogers N. Retinal function as a marker for cell membrane omega-3 fatty acid depletion in schizophrenia: a pilot study. Biol Psychiatry 1999, 45: 1138-1142.
  204. Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 2003, CD001257.
  205. Peet M. Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results. Prostaglandins Leukot Essent Fatty Acids Acids 2003, 69: 477-485.
  206. Peet M. Nutrition and schizophrenia: beyond omega-3 fatty acids. Prostaylandins Leukot Essent Fatty Acids 2004, 70: 417-422.
  207. Peet M, Horrobin DF, E-E Muticentre group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002, 36: 7-18.
  208. Peet M, Brind-J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001, 49: 243-251.
  209. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001, 158: 2071-2074.
  210. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 2003, 62: 195-204.
  211. Su KP, Shen WW, Huang SY. Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. Eur Neuropsychopharmacol 2001, 11: 295-299.
  212. Richardson AJ, Easton T, Puri BK. Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid. Eur Neuropsychopharmacol 2000, 10: 189-193.
  213. Puri BK, Richardson AJ, Horrobin DF, Easton T, Saeed N, Oatridge A, Hajnal JV, Bydder GM. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. Int J Clin Pract 2000, 54: 57-63.
  214. Richardson AJ, Easton T, Gruzelier JH, Puri BK. Laterality changes accompanying symptom remission in schizophrenia following treatment with eicosapentaenoic acid. Int J Psychophysiol 1999, 34: 333-339.
  215. American Psychiatric Association. Diagnostic and statistical manual for mental disorders (DSM-IV). Washington DC, APA, 1994.
  216. Hibbeln JR, Salem N. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr 1995, 62: 1-9.
  217. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998, 43: 315-319.
  218. Logan AC. Neurobehavioural aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression. Altern Med Rev 2003, 8: 410-425.
  219. Mischoulon D, Fava M. Docosahexaenoic acid and omega-3 fatty acids in depression. Psychiatr Clin North Am 2000, 23: 785-794.
  220. Noaghiul S, Hibbeln JR. Cross national relationship of seafood consumption and rates of bipolar disorders. Am J Psychiatry 2003, 160: 2222-2227.
  221. Hibbeln JR. Fish consumption and major depression. Lancet 1998, 351: 1213.
  222. Tanskanen A, Hibbeln JR, Tuomilehto J, Uutela A, Haukkala A, Viinamaki H, Lehtonen J, Vartiainen E. Fish consumption and depressive symptoms in the general population in Finland. Psychiatr Serv 2001, 52: 529-531.
  223. Suzuki S, Akechi T, Kobayashi M, Taniguchi K, Goto K, Sasaki S, Tsugane S, Nishiwaki Y, Miyaoka H, Uchitomi Y. Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer. Br J Cancer 2004, 90: 787-793.
  224. Frasure-Smith N, Lesperance F, Julien P. Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes. Biol Psychiatry 2004, 55: 891-896.
  225. De Vriese SR, Christophe AB, Maes M. In humans, the seasonal variation in poly-unsaturated fatty acids is related to the seasonal variation in violent suicide and serotonergic markers of violent suicide. Prostaglandins Leukot Essent Fatty Acids 2004, 71: 13-18 [CrossRef].
  226. Hakkarainen R, Partonen T, Haukka J, Virtamo J, Albanes D, Lonnqvist J. Is low dietary intake of omega-3 fatty acids associated with depression? Am J Psychiatry 2004, 161: 567-569.
  227. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998, 48: 149-155.
  228. Assies J, Lok A, Bockting CL, Weverling GJ, Lieverse R, Visser I, Abeling NGGM, Duran M, Schene AH. Fatty acids and homocysteine levels in patients with recurrent depression: an explorative pilot study. Prostaglandins Leukot Essent Fatty Acids 2004, 70: 349-356.
  229. Mamalakis G, Kiriakakis M, Tsibinos G, Kafatos A. Depression and adipose polyunsaturated fatty acids in the survivors of the Seven Countries Study population of Crete. Prostaglandins Leukot Essent Fatty Acids 2004, 70: 495-501.
  230. Tiemeier H, van Tuijl HR, Hofman A, Kiliaan AJ, Breteler MM. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam study. Am J Clin Nutr 2003, 78: 40-46.
  231. Mamalakis G, Tornaritis M, Kafatos A. Depression and adipose essential polyunsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 2002, 67: 311-318.
  232. Mamalakis G, Kiriakakis M, Tsibinos G, Kafatos A. Depressin and adipose polyunsaturated fatty acids in an adolescent group. Prostaglandins Leukot Essent Fatty Acids 2004, 71: 289-294.
  233. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H. Fatty acid composition in major depression: decreased $\omega$3 fractions in cholesteryl esters and increased C20:4 $\omega$6/C20:5 $\omega$3 ration in cholesteryl esters and phospholipids. J Affect Disord 1996, 38: 35-46 [CrossRef].
  234. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999, 85: 275-291.
  235. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB, Mahadik SP. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121: 109-122.
  236. Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996, 31 (Suppl): S157-S161.
  237. Hibbeln JR. Seafood consumption, the DHA content of mothers' milk and prevalance rates of postpartum depression: a cross-national, ecological analysis. J Affect. Disord. 2002, 69: 15-29 [CrossRef].
  238. Makrides M, Crowther CA, Gibson RA, Gibson RS, Skeaff CM. Docosahexaenoic acid and post-partum depression-is there a link? Asia Pac J Clin Nutr 2003, 12 (Suppl): S37.
  239. Otto SJ, de Groot RH, Hornstra G. Increased risk of postpartum depressive symptoms is associated with slower normalization after pregnancy of the functional docosahexaenoic status. Prostaglandins Leukot Essent Fatty Acids 2003, 69: 237-243.
  240. De Vriese SR, Christophe AB, Maes M. Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-3 PUFAs are related to major depression. Life Sci 2003, 73: 3181-3187.
  241. Peet M, Horrobin DF. A dose-ranging study of the effects ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002, 59: 913-919.
  242. Puri BK, Counsell SJ, Hamilton G, Richardson AJ, Horrobin DF. Eicosapentaenoic acid in treatment resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover. Int J Clin Pract 2001, 55: 560-563.
  243. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002, 159: 477-479.
  244. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003, 13: 267-271 [CrossRef].
  245. Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HF, Puryear LJ. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003, 160: 996-998 [CrossRef].
  246. Marangell LB, Martinez JM, Zboyan HA, Chong H, Puryear LJ. Omega-3 fatty acids for prevention of postpartum depression: negative data from a preliminary, open-label pilot study. Depress Anxiety 2004, 19: 20-23 [CrossRef].
  247. Llorente AM, Jensen CL, Voigt RG, Fraley JK, Berretta MC, Heird WC. Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. Am J Obstet Gynecol 2003, 188: 1348-1353.
  248. Taylor KE, Higgins CJ, Calvin CM, Hall JA, Easton T, McDaid AM, Richardson AJ. Dyslexia in adults is associated with clinical signs of fatty acid deficiency. Prostaglandins Leukot Essent Fatty Acids 2000, 63: 75-78.
  249. Richardson AJ, Calvin CM, Clisby C, Schoenheimer DR, Montgomery P, Hall JA, Hebb G, Westwood E, Talcott JB, Stein JF. Fatty acid deficiency signs predict the severity of reading and related difficulties in dyslexic children. Prostaglandins Leukot Essent Fatty Acids 2000, 63: 69-74.
  250. Richardson AJ, Cox IJ, Sargentoni J, Puri BK. Abnormal cerebral phospholipid metabolism in dyslexia indicated by phosphorus-31 magnetic resonance spectroscopy. NMR Biomed 1997, 10: 309-314.
  251. MacDonnell LEF, Skinner FK, Ward PE, Glen AI, Glen AC, Macdonald DJ, Boyle RM, Horrobin DF. Increased levels of cytosolic phospholipase A2 in dyslexics. Prostaglandins Leukot Essent Fatty Acids 2000, 63: 95-100.
  252. Stordy BY. Dark adaptation, motor skills, docosahexaenoic acid, and dyslexia. Am J Clin Nutr 2000, 71 (Suppl 1): 323S-326S.
  253. Vancassel S, Durand G, Barthelemy C, Lejeune B, Martineau J, Guilloteau D, Andres C, Chalon S. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids 2001, 65: 1-7.
  254. Bell JG, Sargent JR, Tocher DR, Dick JR. Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: a characteristic abnormality in neurodevelopmental disorders? Prostaglandins Leukot Essent Fatty Acids 2000, 63: 21-25.
  255. Richardson AJ. Clinical trials of fatty acid treatment in ADHD, dyslexia, dyxpraxia and the autistic spectrum. Prostaglandins Leukot Essent Fatty Acids 2004, 70: 383-390 [CrossRef].
  256. Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 2003, 160: 167-169 [CrossRef].
  257. Fux M, Benjamin J, Nemets B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. J Psychiatr Res 2004, 38: 323-325.
  258. Hibbeln JR. Seafood consumption and homicide mortality. World Rev Nutr Diet 2001, 88: 41-46.
  259. Iribarren C, Markovitz JH, Jacobs DR Jr, Schreiner PJ, Daviglus M, Hibbeln JR. Dietary intake of n-3, n-6 fatty acids and fish: relationship with hostility in young adults - the CARDIA study. Eur J Clin Nutr 2004, 58: 24-31 [CrossRef].
  260. Hamazak T, Thienprasert A, Kheovichai K, Samuhaseneetoo S, Nagasawa T, Watanabe S. The effect of docosahexaenoic acid on aggression in elderly Thai subjects - a placebo controlled double blind study. Nutr Neurosci 2002, 5: 37-41.
  261. Hamazaki T, Sawazaki S, Itomura M, Asaoka E, Nagao Y, Nishimura N, Yazawa K, Kuwamori T, Kobayashi M. The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J Clin Invest 1996, 97: 1129-1133.
  262. Sawazaki S, Hamazaki T, Yazawa K, Kobayashi M. The effect of docosahexaenoic acid on plasma catecholamine concentrations and glucose tolerance during long-lasting psychological stress: a double-blind placebo-controlled study. J Nutr Sci Vitaminol 1999, 45: 655-665.
  263. Hamazaki T, Sawazaki S, Nagao Y, Kuwamori T, Yazawa K, Mizushima Y, Kobayashi M. Docosahexaenoic acid does not affect aggression of normal volunteers under nonstressful conditions. A randomized, placebo-controlled, double-blind study. Lipids 1998, 33: 663-667.
  264. Buydens-Branchey L, Branchey M, McMakin DL, Hibbeln JR. Polyunsaturated fatty acid status and aggression in cocaine addicts. Drug Alcohol Depend 2003, 71: 319-323.
  265. Available from URL: pdf [consulted: 13 Sept 2004].
  266. Nutrition Facts "Omega 3" eggs, Gray Ridge Egg Farms, RR#7, Strathroy, ONN7G 3H8.
  267. Available from URL: http://www.dairy-oh. com/nutrition.htm [consulted: 13 Sept 2004].
  268. Available from URL: au/driver.asp?page=main/brands/bread/up+omega+3+dha [consulted: 13 Sept 2004].